Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 2,476 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HSCT Clear all

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Retinoblastoma
Interventions: filgrastim, carboplatin, etoposide, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: Up to 18 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 3
States / cities: St Louis, Missouri • Buffalo, New York • Houston, Texas

Conditions: Allogeneic Hematopoietic Cell Transplantation
Interventions: TCRαβ+/CD19+ depleted allogeneic hematopoietic stem cell transplant (HSCT); Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Other Cancer
Interventions: Mobile App + enhanced standard care, Enhanced Standard Care; Behavioral · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematological Malignancies
Interventions: Full intensity, double umbilical cord, stem cell transplant, Flu/Bu4 conditioning regimen, Total Lymphoid Irradiation (TLI), Graft versus Host Disease prevention (GVHD prophylaxis), Mycophenolate Mofetil; Procedure · Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Up to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Kidney Cancer
Interventions: dactinomycin, filgrastim, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, vincristine sulfate, conventional surgery, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2006
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia in Relapse, Burkitt's Lymphoma Stage III, Burkitt's Lymphoma Stage IV, Type 3 Diffuse Large B-Cell Lymphoma
Interventions: Individualized Yoga Intervention Group, iPad Activity Control Group; Behavioral · Other
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 8 Years to 18 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Graft Versus Host Disease, GVHD
Interventions: tacrolimus, sirolimus, fludarabine, busulfex; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematopoietic Stem Cell Transplant
Interventions: Music Therapy, No Music Therapy; Behavioral
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Distress, Hematopoietic Stem Cell Transplantation
Interventions: Problem Solving Education; Behavioral
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hematopoietic Stem Cell Transplantation
Interventions: Interval Exercise Training/Motivational Accelerometry; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Graft-vs-Host Disease
Interventions: Recombinant Human Keratinocyte Growth Factor (rHuKGF); Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: 3 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: AML, MDS
Interventions: TSC-101, Control; Drug · Other
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 26
States / cities: Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 21 more

Conditions: Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions: Reduced Intensity Allogeneic Transplant, Fludarabine, Busulfan, Campath; Procedure · Drug
Lead sponsor: New York Medical College; Other
Eligibility: 7 Years to 50 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Epidermolysis Bullosa
Interventions: Cyclophosphamide, Fludarabine, Anti-thymocyte globulin, Myeloablative Busulfan, Mesenchymal stem cell transplantation, Total body irradiation, Bone marrow or umbilical cord blood (UCG) stem cell transplantation; Drug · Procedure · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 25 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Systemic Lupus Erythematosus
Interventions: Allogeneic Stem Cell Transplantation; Biological
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Leukemia, Acute Lymphoblastic Leukemia
Interventions: gene-modified T cells targeted; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia
Interventions: Not listed
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
Interventions: muromonab-CD3, natural killer cell therapy, fludarabine phosphate, methotrexate, thiotepa, gene expression analysis, flow cytometry, immunologic technique, allogeneic hematopoietic stem cell transplantation, in vitro-treated peripheral blood stem cell transplantation, total-body irradiation; Biological · Drug · Genetic + 3 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 45 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, UV light therapy, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Chronic Graft-versus-host Disease, Chronic GVHD, cGVHD
Interventions: Tele-palliative care visit; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma
Interventions: Pack Health's digital life coaching (DLC); Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute, Myeloproliferative-Myelodysplastic Diseases, Lymphoma, Malignant
Interventions: Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients, Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies, Hematopoietic Progenitor Cell Transplantation (HPCT), CNS radiation treatment for ALL with prior CNS disease patients; Drug · Other · Radiation
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: Up to 21 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor, T-cell replete HSCT from a related, haploidentical donor; Biological · Drug · Procedure
Lead sponsor: Kiadis Pharma; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 8 more

Search by objective public record fields.

Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer

TCRαβ+/CD19+ Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Malignant and Non-malignant Disorders

Multimodal Mobile Intervention Application (App) to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors

Trial Of Double Umbilical Cord Blood Transplantation

Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors

Yoga Fatigue Study

Tacrolimus and Sirolimus as Prophylaxis After Allogenic Non-myeloablative Peripheral Blood Stem Cell Transplantation

Music Therapy and Hematopoietic Stem Cell Transplant

Motivations, Expectations, and Decision-making of Sickle Cell Patients in Clinical Research

Problem-Solving Education for Caregivers and Patients During Stem Cell Transplant

Fitness in Allogeneic Stem Cell Transplantation

Keratinocyte Growth Factor to Prevent Acute GVHD

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs

Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Tele-Palliative Care Intervention for Patients With Chronic Graft-Versus-Host Disease

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer